CIK 0000730272 · Large accelerated filer
REPLIGEN CORP
Sign in to watch- Ticker
- RGEN
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 042729386
- Phone
- 7814499560
- Business address
- 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM, MA, 02453
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $5,953,260
- in 5 filings, $6.0M under 10b5-1 plans
Net −$5,953,260. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-06 | Douglass Brian Robb CHIEF PRODUCT OFFICER | Grant or award | +700 | 8,685 | ||
| 2026-10-06 | Douglass Brian Robb CHIEF PRODUCT OFFICER | Grant or award · Stock Option (Right to Buy) | +675 | 675 | ||
| 2026-10-05 | Loeillot Olivier Chief Executive Officer | Sale 10b5-1 | −1,333 | $178.75 | $238K | 45,788 |
| 2026-10-05 | Loeillot Olivier Chief Executive Officer | Option exercise 10b5-1 | +4,202 | $154.96 | $651K | 49,990 |
| 2026-10-05 | Loeillot Olivier Chief Executive Officer | Sale 10b5-1 | −4,202 | $190.00 | $798K | 45,788 |
| 2026-10-05 | Loeillot Olivier Chief Executive Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −4,202 | 8,405 | ||
| 2026-10-02 | Loeillot Olivier Chief Executive Officer | Shares withheld for taxes | −1,248 | $181.70 | $227K | 47,121 |
| 2026-09-25 | Garland Jason K CFO | Shares withheld for taxes | −421 | $189.68 | $80K | 18,408 |
| 2026-09-24 | Loeillot Olivier Chief Executive Officer | Option exercise 10b5-1 | +8,404 | $154.96 | $1.3M | 56,773 |
| 2026-09-24 | Loeillot Olivier Chief Executive Officer | Sale 10b5-1 | −8,404 | $190.00 | $1.6M | 48,369 |
| 2026-09-24 | Loeillot Olivier Chief Executive Officer | Option exercise 10b5-1 | +4,542 | $155.38 | $706K | 52,911 |
| 2026-09-24 | Loeillot Olivier Chief Executive Officer | Sale 10b5-1 | −4,542 | $190.00 | $863K | 48,369 |
| 2026-09-24 | Loeillot Olivier Chief Executive Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −8,404 | 12,607 | ||
| 2026-09-24 | Loeillot Olivier Chief Executive Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −4,542 | 9,085 | ||
| 2026-09-21 | Loeillot Olivier Chief Executive Officer | Option exercise 10b5-1 | +5,426 | $141.79 | $769K | 53,795 |
| 2026-09-21 | Loeillot Olivier Chief Executive Officer | Sale 10b5-1 | −5,426 | $180.00 | $977K | 48,369 |
| 2026-09-21 | Loeillot Olivier Chief Executive Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −5,426 | 5,426 | ||
| 2026-09-04 | Loeillot Olivier Chief Executive Officer | Sale 10b5-1 | −3,035 | $165.90 | $504K | 48,369 |
| 2026-09-03 | Loeillot Olivier Chief Executive Officer | Shares withheld for taxes 10b5-1 | −2,842 | $169.61 | $482K | 51,404 |
| 2026-09-01 | Hughes Violetta CHIEF ACCOUNTING OFFICER | Shares withheld for taxes | −277 | $170.02 | $47K | 6,331 |
Page 1 of 11 · 215 trades